Drug-induced cognitive impairment is a common condition caused by many different prescribed medications, and is characterized by deficits involving multiple cognitive domains including memory. Drosophila models have been used to investigate chemotherapy-induced cognitive impairment (CRCI), characterizing the neurotoxicity of the chemotherapeutic drugs cisplatin, cyclophosphamide, and doxorubicin.
Five day old adults were fed chemotherapy drugs at three concentrations for three days, then assessed at 10, 20, or 30 days with neurological and neurocognitive testing (climbing assay, taste memory assay). Flies treated with chemotherapy drugs showed impaired climbing ability at 10 days. Flies treated with cisplatin or doxorubicin demonstrated impaired neurocognitive function as assessed by the taste memory assay.
Tissue analysis was performed on cisplatin treated adult flies. Treated flies displayed increased levels of caspase activation, vacuolar neurodegeneration, elevated DNA damage, and elevated oxidative stress. Effects were more marked at higher cisplatin dosages (FBrf0257941).
See the FlyBase chemical reports for cisplatin (FBch0000748), cyclophosphamide (FBch0000076), doxorubicin (FBch0000426).
[updated Apr. 2024 by FlyBase; FBrf0222196]
Cognitive impairment subsequent to cancer chemotherapy has been well-documented. Observed difficulties include impairment in the domains of memory, attention, executive function, processing speed, visual and verbal memory, and language (Pendergrass, et al., 2018; pmid:29497579).